Cost Effectiveness and Resource Allocation Cost-effectiveness Analysis for Joint Pain Treatment in Patients with Osteoarthritis Treated at the Instituto Mexicano Del Seguro Social (imss): Comparison of Nonsteroidal Anti-inflammatory Drugs (nsaids) vs. Cyclooxygenase-2 Selective Inhibitors

Background: Osteoarthritis (OA) is one of the main causes of disability worldwide, especially in persons >55 years of age. Currently, controversy remains about the best therapeutic alternative for this disease when evaluated from a cost-effectiveness viewpoint. For Social Security Institutions in developing countries, it is very important to assess what drugs may decrease the subsequent use of medical care resources, considering their adverse events that are known to have a significant increase in medical care costs of patients with OA. Three treatment alternatives were compared: celecoxib (200 mg twice daily), non-selective NSAIDs (naproxen, 500 mg twice daily; diclofenac, 100 mg twice daily; and piroxicam, 20 mg/day) and acetaminophen, 1000 mg twice daily. The aim of this study was to identify the most cost-effective first-choice pharmacological treatment for the control of joint pain secondary to OA in patients treated at the Instituto Mexicano del Seguro Social (IMSS).

[1]  Jordi Castellsague,et al.  Hospitalization for peptic ulcer and bleeding in users of selective COX‐2 inhibitors and nonselective NSAIDs with special reference to celecoxib , 2008, Pharmacoepidemiology and drug safety.

[2]  P. Delmas,et al.  Biological markers in osteoarthritis , 2007, Nature Clinical Practice Rheumatology.

[3]  A. Dray,et al.  Arthritis and pain. Future targets to control osteoarthritis pain , 2007, Arthritis research & therapy.

[4]  S. Reichenbach,et al.  Meta-analysis: Chondroitin for Osteoarthritis of the Knee or Hip , 2007, Annals of Internal Medicine.

[5]  J. Brophy,et al.  Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. , 2006, American Journal of Epidemiology.

[6]  E. Altschuler,et al.  Pharmacotherapy of Osteoarthritis , 2006, American journal of physical medicine & rehabilitation.

[7]  E. Ding,et al.  Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. , 2006, JAMA.

[8]  D. Graham.  COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. , 2006, JAMA.

[9]  R. Madhok,et al.  Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis , 2006, Arthritis research & therapy.

[10]  J. Tanne.  Reports cite cardiovascular risks of COX 2 inhibitors and NSAIDs , 2006, BMJ : British Medical Journal.

[11]  F. Gomez-Clavelina,et al.  Políticas sociales contra la pobreza y en favor de la salud en México , 2006 .

[12]  R. Torres-González,et al.  [Rating scale for osteoarthritis knee assessment]. , 2006, Cirugia y cirujanos.

[13]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[14]  S. Abramson,et al.  Current state of therapy for pain and inflammation , 2005, Arthritis research & therapy.

[15]  J. Borer,et al.  Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance , 2005, Arthritis research & therapy.

[16]  F. Contreras,et al.  PCV28 COST-UTILITY ANALYSIS FOR STATINS IN MEXICO , 2005 .

[17]  J. Mejía-Aranguré,et al.  Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: Population-based data , 2005, BMC Cancer.

[18]  S. Litschig,et al.  Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib , 2005, Current medical research and opinion.

[19]  R. Moore,et al.  Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports , 2005, Arthritis research & therapy.

[20]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[21]  R. Dionne,et al.  Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen , 2004, Pain.

[22]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.

[23]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial , 2004, The Lancet.

[24]  A Gibofsky,et al.  Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis , 2004, Annals of the rheumatic diseases.

[25]  M. Doherty,et al.  Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials , 2004, Annals of the rheumatic diseases.

[26]  G. Naglie,et al.  The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[27]  B. Spiegel,et al.  The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis , 2003, Annals of Internal Medicine.

[28]  S. Gabriel,et al.  The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  J. Case,et al.  Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. , 2003, Archives of internal medicine.

[30]  V. Wong,et al.  Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. , 2002, The New England journal of medicine.

[31]  J. Wright.  The double-edged sword of COX-2 selective NSAIDs. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[32]  M. J. Broekman,et al.  COX inhibitors and thromboregulation. , 2002, The New England journal of medicine.

[33]  T. Kvien,et al.  Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis , 2002, Expert review of pharmacoeconomics & outcomes research.

[34]  A. Kivitz,et al.  Comparative Efficacy and Safety of Celecoxib and Naproxen in the Treatment of Osteoarthritis of the Hip , 2001, The Journal of international medical research.

[35]  G. Eisen,et al.  Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I trial , 2001 .

[36]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[37]  J. Bolognese,et al.  Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. , 2000, Archives of internal medicine.

[38]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[39]  P. Isakson,et al.  Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. , 1999, Mayo Clinic proceedings.

[40]  J. Barendregt,et al.  Global burden of disease , 1997, The Lancet.

[41]  S. Cantor,et al.  Cost - Effectiveness Analysis, Extended Dominance, and Ethics , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[42]  P. Wolf,et al.  The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. , 1994, American journal of public health.

[43]  Potential anti-inflammatory role of paracetamol in knee OA , 2007, Nature Clinical Practice Rheumatology.

[44]  J. G. Espinosa,et al.  Higia y Panacea en la salud y la sociedad. Los sistemas de salud, un producto de la evolución social , 2005 .

[45]  D. Graham.  of Acute Myocardial Infarction and Sudden Cardiac Death in Patients Treated with COX-2 Selective and Non-Selective NSAIDs," , 2004 .

[46]  S A Rich,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[47]  M. V. Bolaños.  Revisión crítica a la teoría de la transición epidemiológica , 2000 .

[48]  R H Brook,et al.  Costs attributable to osteoarthritis. , 1998, The Journal of rheumatology.

[49]  N. Bellamy,et al.  Double blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC Osteoarthritis Index. , 1992, The Journal of rheumatology.